Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD04 in early Alzheimer's disease
NCT07107074Phase 2Active, not recruiting
- Sponsor
- ADvantage Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of AD04 in Alzheimer's disease (AD), sponsored by ADvantage Therapeutics. Started Nov 2023; status: active, not recruiting.
02
Drugs
AD04
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07107074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107074.